Financial Summary (All financials)
| In millions, except per share items | Dec-31-22 | Dec-31-21 | Dec-31-20 | Dec-31-19 | Dec-31-18 | Dec-31-17 | Dec-31-16 | Dec-31-15 |
| Revenues | 10,978.0 | 11,869.0 | 5,954.0 | 8,228.0 | 7,674.0 | 7,318.0 | 9,099.0 | 8,739.0 |
| Revenue growth | -7.5% | 99.3% | -27.6% | 7.2% | 4.9% | -19.6% | 4.1% | 3.1% |
| Cost of goods sold | 2,257.0 | 2,078.0 | 2,007.0 | 1,845.0 | 1,729.0 | 1,611.0 | 1,474.0 | 1,422.0 |
| Gross profit | 8,721.0 | 9,791.0 | 3,947.0 | 6,383.0 | 5,945.0 | 5,707.0 | 7,625.0 | 7,317.0 |
| Gross margin | 79.4% | 82.5% | 66.3% | 77.6% | 77.5% | 78.0% | 83.8% | 83.7% |
| Selling, general and administrative | | | | | | | | |
| Sales and marketing | 1,035.0 | 810.0 | 659.0 | 883.0 | 857.0 | 776.0 | 731.0 | 745.0 |
| Research and development | 513.0 | 500.0 | 540.0 | 409.0 | 350.0 | 315.0 | 339.0 | 349.0 |
| General and administrative | 906.0 | 843.0 | 768.0 | 787.0 | 701.0 | 694.0 | 646.0 | 647.0 |
| EBITA | 6,267.0 | 7,638.0 | 1,980.0 | 4,304.0 | 4,037.0 | 3,922.0 | 5,909.0 | 5,580.0 |
| EBITA margin | 57.1% | 64.4% | 33.3% | 52.3% | 52.6% | 53.6% | 64.9% | 63.9% |
| Amortization of intangibles | | | | | | | | 4.0 |
| EBIT | 6,267.0 | 7,638.0 | 1,980.0 | 4,304.0 | 4,037.0 | 3,922.0 | 5,909.0 | 5,576.0 |
| EBIT margin | 57.1% | 64.4% | 33.3% | 52.3% | 52.6% | 53.6% | 64.9% | 63.8% |
| Pre-tax income | 5,742.0 | 7,064.0 | 1,435.0 | 3,835.0 | 3,597.0 | 3,537.0 | 3,656.0 | 3,612.0 |
| Income taxes | 1,350.0 | 1,615.0 | 294.0 | 878.0 | 855.0 | 1,438.0 | 1,263.0 | 1,315.0 |
| Tax rate | 23.5% | 22.9% | 20.5% | 22.9% | 23.8% | 40.7% | 34.5% | 36.4% |
| Net income | 4,304.0 | 5,351.0 | 1,104.0 | 2,908.0 | 2,689.0 | 2,031.0 | 2,339.0 | 2,246.0 |
| Net margin | 39.2% | 45.1% | 18.5% | 35.3% | 35.0% | 27.8% | 25.7% | 25.7% |
| |
| Diluted EPS | $15.48 | $17.84 | $3.60 | $9.09 | $7.79 | $5.43 | $5.76 | $5.13 |
| Shares outstanding (diluted) | 278.0 | 300.0 | 307.0 | 320.0 | 345.0 | 374.0 | 406.0 | 438.0 |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|